Qingdai, a traditional Chinese medicine (TCM) used for the treatment of chronic myeloid leukemia (CML) with good efficacy, has been used in China for decades. However, due to the complexity of traditional Chinese medicinal compounds, the pharmacological mechanism of Qingdai needs further research. In this study, we investigated the pharmacological mechanisms of Qingdai in the treatment of CML using network pharmacology approaches. First, components in Qingdai that were selected by pharmacokinetic profiles and biological activity predicted putative targets based on a combination of 2D and 3D similarity measures with known ligands. Then, an interaction network of Qingdai putative targets and known therapeutic targets for the treatment of chronic myeloid leukemia was constructed. By calculating the 4 topological features (degree, betweenness, closeness, and coreness) of each node in the network, we identified the candidate Qingdai targets according to their network topological importance. The composite compounds of Qingdai and the corresponding candidate major targets were further validated by a molecular docking simulation. Seven components in Qingdai were selected and 32 candidate Qingdai targets were identified; these were more frequently involved in cytokine-cytokine receptor interaction, cell cycle, p53 signaling pathway, MAPK signaling pathway, and immune system-related pathways, which all play important roles in the progression of CML. Finally, the molecular docking simulation showed that 23 pairs of chemical components and candidate Qingdai targets had effective binding. This network-based pharmacology study suggests that Qingdai acts through the regulation of candidate targets to interfere with CML and thus regulates the occurrence and development of CML.
Background
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell proliferation-induced myeloproliferative disease [1] . It has high heterogeneity and distinct molecular genetic features -the unique cytogenetic features of CML are Philadelphia chromosome t (9; 22) (q34; q11) -in which the c-ABL protooncogene on the long arm of chromosome 9 translocates to the BCR of the long arm of chromosome 22, forming an BCR-ABL fusion gene [2, 3] , and it has become an important topic of research. Imatinib mesylate and the newer BCR-ABL tyrosine kinase inhibitors are the standard therapy for CML [4] , which greatly improves the survival of patients with chronic myeloid leukemia; however, drug resistance and adverse effects remain a problem [5] . Therefore, looking for new strategies to improve the treatment of chronic myeloid leukemia treatment has important clinical significance.
Chinese herbal medicine is a unique medicine used in Chinese medicine to prevent and treat diseases. With the development of medicine around the world, China's ancient Chinese medicine system is receiving the attention of the world. However, it is the most important and difficult task for Chinese traditional medicine to elucidate the interaction between the complex chemical systems of traditional Chinese medicine and the complex systems of diseases and syndromes. Qingdai is prepared as clumps of dry powder, obtained by machining the leaves or stems of Strobilanthes cusia, Polygonum tinctorium Ait, and Isatis indigotica Fort (Pharmacopoeia of the People's Republic of China, 2010) . Qingdai is one herb in Qing Huang San, which has been recorded in the "Jing Yue Quan Shu," "Shi Yi De Xiao Fang," "Qi Xiao Liang Fang," and so on, and is Professor Zhou Aixiang's classical prescription of CML treatment [6] . As confirmed by research, indirubin, a component of Qingdai, is indeed effective in the treatment of chronic myeloid leukemia [7] . Dai et al. treated K562 cells with different concentrations of Qingdai compound (2.5, 5, 7.5, 10, and 20 ug/ml) and harvested them at 24 h, reporting that the Qingdai compound inhibited proliferation and promoted apoptosis in K562 cells. Then, the expression of bcr/abl and JWA was detected by semi-quantitative RT-PCR, and concentration-dependent decreases were found in bcr-abl and JWA expression of K562 cells. It was proved that the Qingdai compound can partially promote the apoptosis of K562 cells by inhibiting the expression of bcr/abl and JWA in K562 cells [8] ; however, its specific mechanism needs further study. Therefore, it is necessary to develop a novel strategy to understand the biological processes of the interactions among drugs, genes, and proteins at a systems level in order to discover the molecular mechanisms related to the therapeutic efficacy of TCM.
In recent years, with the continuous innovation and development of systems biology, network pharmacology and molecular docking provide feasible research strategies for exploring the intrinsic principles of effective intervention of traditional Chinese medicine (TCM) components and building multi-target precise treatment modes for TCM [9, 10] . It has been successfully applied to the molecular network level understanding of the pharmacological mechanism of TCM. For example, in the treatment of diabetes mellitus, Huangqi and Huanglian showed the synergistic mechanism [11] , and through these research strategies we demonstrated the important pharmacological mechanism of Yin huang Qing fei capsule in treating chronic bronchitis [12] .
We based the present study on network pharmacology strategies to decipher the pharmacological mechanisms of Qingdai acting on CML. We offer a systems strategy: (1) We collected the chemical components of Qingdai and downloaded structure and screening index data; (2) We predicted putative targets of Qingdai and analyzed putative targets by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis; (3) We collected the known therapeutic targets of drugs in the treatment of CML; (4) We analyzed and investigated the network between putative targets of Qingdai and known therapeutic targets of CML, which provide a strategy for the further study of the pharmacological mechanism of Qingdai on CML; (5) We performed molecular docking between the molecular compounds of Qingdai and the major targets to validate our findings using a computer-aided drug design method. We expected to achieve our experimental goals with this series of experimental methods.
Material and Methods
The technical strategy of this research is shown in Figure 1 .
Data preparation

Active compounds of Qingdai
Compositive compounds of Qingdai were obtained from TCMSP Database and Literature database. TCMSP (http://ibts.hkbu. edu.hk/LSP/tcmsp.php), updated in 2014-05-31) [13] , which is based on the framework of systems pharmacology for herbal medicines, consists of all the 499 Chinese herbs registered in the Chinese pharmacopoeia with 29 384 ingredients and 12 important ADME-related properties are provided for drug screening and evaluation. Then, through literature mining to prevent omissions, we set the criteria of OB greater than 30%, DL greater than 0.18, and Caco-2 greater than -0.14. When they met these criteria, these components were used as candidate compounds for further analysis. We collected information on 7 compounds and obtained the name of the molecule and its chemical structure. We obtained the molecular Smiles format through the PubChem (https://pubchem.ncbi.nlm.nih. gov/) database.
Known therapeutic targets of drugs in the treatment of chronic myelocytic leukemia
The known therapeutic targets of drugs in the treatment of chronic myeloid leukemia were obtained in 3 ways: PubMed (https://www.ncbi.nlm.nih.gov/pubmed,2017-7-31), DrugBank20 (http://www.drugbank.ca/, version 5.0.10, released 2017- [11] [12] [13] [14] , and the Online Mendelian Inheritance in Man (OMIM) database (http://www.omim.org/, released on 2017-12-20) [14] . In the PubMed database, "chronic myeloid leukemia" was retrieved, and the restriction was "gene" and "Homo sapiens." We verified the accuracy of the genes by consulting the literature related to these genes. In total, 252 known therapeutic targets 
Prediction of targets of Qingdai
Obtaining the target of Qingdai through experiments requires a great deal of manpower, material, and financial resources. To accurately predict the targets of bioactive molecules based on a combination of 2D and 3D similarity measures with known ligands, we used the web server Swiss Target Prediction (http://www.swisstargetprediction.ch/) to predict the putative targets of the active compounds of Qingdai. Predictions can be carried out in 5 different organisms, and mapping predictions by homology within and between different species is enabled for close paralogs and orthologs [15] . The "smiles" formats of 7 active compounds were imported into Swiss Target Prediction to predict their putative targets of action. It is noteworthy that the predicted putative target is limited to Homo sapiens, and to improve the reliability of predictions goal, only a high probability of target selected. A total of 112 therapeutic putative targets were obtained. 
Network construction
Three types of visual networks were built: 1) The compound-target network (C-T network) is an interaction network using the active compounds of Qingdai and its corresponding putative targets.
2) The target-pathway network (T-P network) is composed of the putative targets and corresponding pathways.
3) The target-target network (T-T network) was built using the relationship between the putative targets of Qingdai and known therapeutic targets of the CML.
Cytoscape 3.5.1 (http://www.cytoscape.org/) is an open software application for visualizing, integrating, modeling, and analyzing interactive networks. All the networks were built using it.
Analysis of the target-target network (Qingdai putative target-known therapeutic targets of the CML network).
Li et al. [16] suggested that "If the degree of a node is more than 2 times the median degree of all the nodes in a network, the node may function as a big hub." The topological features of the target-target network are analyzed by several important topological properties, such as "degree" [17] , "betweenness" [17] , "closeness" [17] , and "coreness" (an iterative process in which nodes are removed from the network with minimal connection order) [18] . The larger a protein's degree/ node betweenness/closeness centrality, the more important that protein is in the PPI network [19] . Subsequently, the targets were screened for topological importance. Then, the major hubs were screened. The DAVID webserver was used to perform KEGG pathway enrichment analysis of the main targets.
Molecular docking simulation
We used computer molecular docking simulation techniques to verify the credibility of the study. SystemsDOCK (http://systemsdock.unit.oist.jp/) was used for molecule docking [20] . SystemsDock is a web server for network pharmacology-based prediction and analysis that permits docking simulation and molecular pathway mapping for comprehensive characterization of ligand selectivity and interpretation of ligand action on a complex molecular network. All the compounds and 3D structures of Qingdai were directly downloaded from the PubChem database (https://pubchem.ncbi.nlm. nih.gov/, 2017-11-26), and we obtained the 3D structures of target genes from Uniprot (http://www.uniprot.org/, 2017-11) and PDM databases (http://www.rcsb.org/pdb/home/home.do). Docking scores were used to assess the binding affinities of compounds to the respective candidate target.
Results
Active compounds in Qingdai
A single Chinese medicine contains a large number of compounds, so it is helpful to identify these active compounds by means of network pharmacological virtual screening. A total of 53 compounds in Qingdai were obtained. Then, 3 ADME (absorption, distribution, metabolism, and excretion)-related models, including OB, DL, and Caco-2, were used to screen most of the active compounds from Qingdai. Finally, we selected 7 compounds from Qingdai (Table 1) , and after text mining, found that most of these compounds possess potent pharmacological activities, such as indirubin, the main active and characteristic compound in Qingdai. Research shows that indirubin and its derivatives can be used to treat chronic myelogenous leukemia by potently inhibiting the Signal Transducer and Activator of Transcription 5 (Stat5) protein in CML cells [21] , and indirubin and its derivatives could have anti-angiogenic activity [22] . Studies on Qingdainone have shown anti-tumor and anti-inflammatory effects [23] . Quindoline can cause cell cycle arrest, resulting in inhibition of cell proliferation and causing cell apoptosis [24] . Bisindigotin was found to dose-dependently inhibit TCDD-induced ethoxyresorufin O-demethylase (EROD) activity to achieve an anti-tumor effect [25] . Isoindigo can mediate the cell proliferation pathway to promote apoptosis [26, 27] . Beta-sitosterol could inhibit the growth of bacteria and was found to be anti-inflammatory [28] . Indirubin and Indigotin were determined to be the quality markers of Qingdai in the Chinese Pharmacopoeia (The State Pharmacopoeia Commission of China, 2015).
Putative targets of Qingdai
For Qingdai, through putative target prediction for the 7 components, a total of 112 targets were obtained. Cyclin-dependent kinases (CDKs) are involved in regulating both cell cycle and transcription. Indirubin inhibits CDK activity by K562 cell cycle arrest and promotes apoptosis [29, 30] . With Quindoline, through prediction, MAPKs (mitogen-activated protein kinase) and CLKs were obtained. MAPKs play key roles in many cell proliferation-related signaling pathways [31] . Research by Ahmed K found in cancer cells that CLKs control the supply of full-length, functional mRNAs coding for a variety of proteins essential for cell growth and survival. Thus, inhibition of CLKs might become a novel anticancer strategy, leading to a selective depletion of cancer-related proteins after turnover [17] . b-sitosterol has antioxidant activity in a complex system [32] . Interestingly, 28 of the 112 putative target genes are common targets for one or more of these components, indicating that these components may be acting on some of the same biological processes or pathways, which reflects a synergistic effect between the individual components of TCM.
The C-T network was constructed to visualize and explain the complex relationship between the active compounds of Qingdai and its putative targets ( Figure 2 ).
GO enrichment and KEGG pathway analysis of the putative targets
The GO and KEGG enrichment analysis were used to comment on the 112 putative targets of Qingdai. As shown in the results of the enrichment, a total of 433 GO enrichment results were obtained, including biological process (BP) (310 terms), molecular function (MF) (86 terms), and cellular component (CC) (38 terms). We set the level of statistical significance at P<0.05. Then, the top 10 significantly enriched terms were selected in the BP, MF, and CC categories listed in Figure 3 . GO enrichment analysis showed that Qingdai can inhibit protein kinase phosphorylation and protein kinase to inhibit cell proliferation, block the cell signaling pathway to inhibit cell proliferation, and promote apoptosis. In addition, chemokines inhibit tumor growth and development by activating immunocompetent cytotoxic cells or inhibiting tumor-associated angiogenesis. In addition, Qingdai can be organized by cell division cycle of proliferation to inhibit cell proliferation or cell mitosis. In addition, it acts on GPCRs, which are closely related to biological behaviors such as the proliferation, invasion, and metastasis of tumors, involving the classical signal pathways such as ERK/MAPK [33] . In recent years, studies have shown that it can serve as a new target for anti-tumor drugs [34] . It is possible that the role of Qingdai on CML is through these molecular mechanisms.
The putative targets of active compounds were mapped onto the 26 KEGG pathways (Figure 4 ). The neuroactive ligand-receptor interaction pathway showed the highest number of target connections (count=13), and cytokine-cytokine receptor interaction with 12 targets, pathways in cancer with 11, and included the focal adhesion, cell cycle, chemokine signaling pathway, MAPK signaling pathway, and p53 signaling pathway, respectively. These pathways have well-established roles in the inhibition of tumor cell growth and differentiation and promote tumor cell apoptosis. In addition, there are numerous signaling pathways involved in immunity and inflammation, such as Toll-like receptor signaling pathways, T cell receptor signaling pathway, and Fc epsilon RI signaling pathway. These pathways play an important role in the infection caused by chronic myeloid leukemia. These pathways of the targets show that Qingdai has a therapeutic effect for a variety of malignant tumors, endocrine disease, and inflammatory diseases. Details are provided in Table 2 . Pharmacological mechanisms of Qingdai acting on chronic myeloid leukemia
The link between traditional Chinese medicine and disease is complex. To illustrate the basic relationship between them, the T-T network was performed for analysis. T-T network consisted of 571 nodes and 10 169 edges. The major hubs in the hub interaction network were determined by calculating 4 features: "degree," "node betweenness," "closeness", and "K value". There were 195 major hubs, including 32 Qingdai targets (Table 3 ) and 168 known therapeutic targets of chronic myeloid leukemia. Interestingly, there were 11 targets that were common to both that were screened. Then, a network of major hubs based on their direct interactions was constructed ( Figure 5 ).
To further decipher the pharmacological mechanism by which Qingdai affects CML, pathway enrichment analysis was performed using the KEGG pathway database. We found that the major hubs were significantly related to various physiological processes, mainly concentrated in 5 annotation clusters, including epidermal growth factor receptor signaling pathways for cell growth, proliferation, differentiation and metabolism, malignant pathways, immune and inflammation-related pathways, and angiogenesis-related pathways. Chronic myeloid leukemia is a malignant proliferative disease of bone marrow hematopoietic cells and is closely related with ErbB receptor overexpression [35] . ErbB receptor signaling regulates cell proliferation, migration, differentiation, apoptosis, and cell migration through Akt, MAPK, and many other pathways. In many forms of malignancy in organs such as the breasts, ovaries, brain, and prostate gland [36] , members of the ErbB family, as well as some of their ligands, are often overexpressed, amplified, or mutated, making them an important therapeutic target [37] . Immune and inflammatory signaling pathways include the Toll-like receptor signaling pathway, T cell receptor signaling pathway, B cell receptor signaling pathway, and Fc epsilon RI signaling pathway. TLR activation has been described to play a role in other leukemias, such as chronic lymphocytic leukemia [38] . T cell receptor (TCR) activation can promote many signal transduction cascades and ultimately determine cell fate by regulating cytokine production, cell survival, proliferation, and differentiation [39] . Regulatory T (Treg) cells can weaken anti-tumor immune responses, which could serve as a promising immuno-therapeutic approach for tumors [40] . The Fc epsilon RI receptor induces multiple signaling pathways that control the secretion of allergic mediators and induction of cytokine gene transcription, resulting in secretion of various molecules: IL-4, IL-5, IL-6, IL-10, IL-13, INF-gamma (interferongamma), and TNF-alpha (tumor necrosis factor alpha) [41] . We provide detailed information of the 20 most meaningful enrichment pathways in Table 4 .
Drug targets reported to be involved in CML pathogenesis for the treatment of CML are involved in cell cycle, growth inhibition, MAPK, ErBb, transforming growth factor beta, and p53 signaling pathways. Interestingly, the 32 Qingdai putative targets included in the major hubs of the T-T network were also included in these pathways. In addition, 32 putative targets were involved in immune and inflammation-related pathways, such as Toll-like receptor, NOD-like receptor, RIG-I-like receptor, and Fc epsilon RI T cell receptor signaling pathway.
To further explore the molecular mechanism of action of Qingdai on CML, we reviewed the literature on the role of Qingdai putative targets in these pathways. Qingdainone, bisindigotin, isoindigo, and indirubin all have target enrichment in the MAPK signaling pathway (MAPK14, MAPT, PDGFRA, PDGFRB, MAPK9, MAPK11, MAPK8, and MAPK10). CD Kang et al. showed that the inhibition of ERK/MAPK induced apoptosis in K562 cells [42] . PDGFRA/B are oncogenes involving tyrosine kinases [43] . Aberrant activity of PTK (protein tyrosine kinases) has been implicated in the stimulation of cancer growth and progression, the induction of drug resistance, tumor neovascularization, tissue invasion, extravasation, and the formation of metastases [44] . We speculate that isoindigo in Qingdai inhibits CML by acting on PDGFRA/B. In the ErbB pathway, GSK3B plays a pivotal role in preserving quiescent HSCs, which has now opened new therapeutic avenues for understanding leukemic stem cell function [45] . Through the cytokine-cytokine receptor interaction, cytokines act on the immune system and hematopoietic system and play an important regulatory role in cell-cell interactions, cell proliferation, differentiation, and effector functions [46] . The p53 protein network regulates important mechanisms in DNA damage repair, cell cycle regulation/checkpoints, and cell senescence and apoptosis, as demonstrated by its ability to positively regulate the expression of various pro-apoptotic genes [47] . In addition, research shows that p53 can stably induce CML cell apoptosis [48] . Cyclin-dependent kinases (CDKS) are a family of serine/threonine kinases that have been firmly established as key regulators of transcription processes underlying coordinated cell cycle entry and sequential progression in nearly all types of proliferative cells [49] . Infection with CML has important secondary symptoms. Enrichment pathways of Qingdai putative targets involve immune and inflammatory pathways, which activate the patient's own immune system and enhance the defence against sources of external infection, such as phagocytosis of immune cells, which plays an essential role in host defence mechanisms by enveloping and destroying infectious pathogens [41] .
In addition, some of the putative targets have a special role in CML. The FMS-like tyrosine kinase 3 (FLT3) gene encodes a class III receptor tyrosine kinase (RTK) that plays important roles in the proliferation, differentiation, and survival of hematopoietic stem and progenitor cells (HSPCs), and FLT3 is frequently mutated and overexpressed in hematologic malignancies [50] . 
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The AGM130 compound is derived from indirubin, which is known as a CDK inhibitor. Research shows that the AGM130 compound efficiently decreased the viability of CML-derived K562 cells, which suggests that AGM130 is a strong candidate for treating Imatinib-resistant CML [51] . In addition, patients with ABCG2 diplotypes might be at higher risk for the rapid and severe development of CML and have a weaker response to treatments with imatinib [52] . We hypothesize that it binds to ABCG2 to enhance the efficacy and reduce the risk of imatinib resistance.
On this basis, the major putative targets of Qingdai that are significantly associated with these biological processes and pathways might play a role in the treatment of CML.
Molecular docking validation
Molecular docking is a rapid method to predict the binding force between traditional Chinese medicine components and the target. It is based on the docking of the ligand and the acceptor's spatial structure. SystemsDock applies AutoDock VINA [53] to perform docking simulation based on the characterized binding interaction and molecular properties [19] . DocK-IN utilizes a machine learning algorithm (Random Forest) together with a series of characterized binding interactions and test compound molecular properties, usually ranging from 0 to 10 (from weak to strong binding) allowing a straightforward indication of binding strength [20] . The 7 compounds of Qingdai and the corresponding candidate major targets were further validated by a molecular docking simulation. As a result, 23 pairs of components of Qingdai and candidate targets had binding efficiencies. Detailed information about the results of molecular docking are described in Supplementary Table 2 . These findings require further experimental verification.
Discussion
In the application of traditional Chinese medicine treatment of CML, Qingdai is given high priority for selection, and has been frequently used in TCM prescriptions. In vitro experiments clearly demonstrated that Qingdai has the ability to inhibit K562 cell proliferation and promote its apoptosis. We used modern network pharmacology and molecular docking technology to explain the effective substance basis and multi-targeting effect of Qingdai treatment of CML. The study of traditional Chinese medicine theory and value is based on the scientific methodology of systematic medicine and has the significance of integrating innovation. In our research, we screened 7 Qingdai active compounds and, from a total of 112 predicted targets of active compounds, obtained 32 major targets of Qingdai for treatment of chronic myeloid leukemia, and enriched 15 signaling pathways related to the treatment of CML. Then, we verified the results of our study by molecular docking. The present study shows the following: 1) By predicting the targets of 7 compounds in Qingdai, we constructed a C-T network and performed GO analysis and KEGG analysis of the putative targets to provide clues to the pharmacology research of Qingdai. 2) We constructed the Qingdai putative target-known therapeutic targets of the CML network, suggesting that Qingdai may affect the disease-related pathways of chronic myeloid leukemia by regulating its candidate targets, such as the cytokine-cytokine receptor interaction, cell cycle, p53 signaling pathway, MAPK signaling pathway, and immune system-related pathways. 3) According to the molecular docking simulation, 23 pairs of components of Qingdai and corresponding putative targets had strong binding efficiencies.
Concusions
Network pharmacology for the study of complex mechanisms of Chinese medicine intervention disease provides new ideas and new methods. This research explored the molecular mechanism of the effects of Qingdai on CML based on these ideas. Our study was based on bioinformatics analysis and computer simulation analysis. Further clinical application assessments and experimental validations for these predicted results are required.
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Supplementary Tables   ESR1  MLL  IMD21  QACR  SLC2  LY75  SFRP1  PTK2B   TP53  HRX  MME  ACRB  SLCO1B1  CBY1  LEF1  ELANE   BCR  HTRX1  CD10  CNGA1  SLC22A8  ARHGAP26  DDIT3   WDSTS  CALLA  KCNMA1  POLB  ST3GAL1  GSTA1  PTCH1   ABCB1  CBL2  NEP  CLCN2  CDA  MIR199B  MECOM  CD247   MTHFR  NSLL  CMT2T  IL17A  NT5E  ST8SIA4  SRSF1  STAT5B   TNF  CLLS5  SCA43  ADRB1  DCTD  ATG4B  CDKN1C  AICDA   JAK2  FLI1  MLF1  TUBB1  ABCC10  MIRLET7I  MIR17  IDH2   IL6  BDPLT21  LPP  CYP2E1  SLC29A1  PTBP2  CRK  AXL   TGFB1  ETV6  CHIC2  VDR  1KBKG  SPRED2  GATA2  CDK9   AKT1  TEL  BTL  MPL  PRKCA  OSBP2  NOTCH2  PMP22   GSTM1  THC5  PBT  CHRM1  IMPDH1  DDX43  PRTN3  ADIPOR1   CTNNB1  KRAS2  RAP1GDS1  CNRM2  IMPDH2  P2RX5  IL32  IKZF1   KRAS  RASK2  TCS1  BCHE  PB1  MKNK2  MIR223  TET2   GSTT1  NS  BST2  UREC  NT5C2  UBASH3B  IL24  MTHFD1L   NFKB1  CFC2  DKCA2  MMP12  ENPP1  MIR30E  ARRB1  NFKB2   BRCA1  RALD  DKCB4  NS5B  PRKCD  ATP5F1  PAX5  ERCC5   MMP9  CMTS  PFBMFT1  ADRB2  MS4A1  KIR2DL5B  WSB1  DAPK1   STAT3  PTPN11  CMM9  PTAFR  HCK  GAS2  CIP2A  POU2F1   ABL1  PTP2C  LIFR  HRH1  CDK2  FAM27E5  KIF11  SPI1   PTGS2  SHP2  SWS  NS5A  MAP2K1  ETNK1  MIR31  SLC22A1   CDKN2A  NS1  STWS  ADRA2A  MAP2K2  MIR1301  BIN1  SEP9   IL1B  JMML  SJS2  ADRA2B  MAP3K2  ST8SIA6  SET   MYC  METCDS  ACSL6  CHD1  1FNAR2  LOC107126288 JUP   GSTP1  CLLS2  FACL6  DRD2  POLA1  LOC107126281 REL   CXCL8  D13S25  ACS2  DRD1  SLC28A3  MIR564  HOXA9   LEP  DBM  IRF1  HTR2A  PARP1  MIR2278  CRKL   TERT  FLVCR2  MAR  OPRM1  PARP2  MIR4701  CSF3R   BCL2  C14orf58  GRAF  PDE4B  PARP3  ABL  SLCO1B3   IFNG  CCT  PDGFR  PANX1  CD22  GF1R  MTHFD1   MTOR  PVHH  IBGC4  CYP3N4  POLE  SPC  IFNAR1   XRCC1  EPV  IMF1  CASR  POLE2  EPHA2  EHMT2   FAS  SERPINA1  PENTT  KCND  POLE3  ICK  CDC6   CCND1  PI  KOGS  HTR7  POLE4  YES1  ADIPOR2   BIRC5  AAT  NSD1  ORM2  PNP  KIT  PER3   GSK3B  TCL1B  ARA267  SLC6A2  C3  FYN  KIR2DS2   MAPK14  TML1  STO  SMPD1  C4A  BTK  EPHB4   ATM  TCL1A  SOTOS1  HTR1A  C4B  NR4A3  MEF2C   MIR21  TCL1  CLLS4  NOMO1  C5  CSK  ASXL1   HMGB1  MYL  DEK  MAP2  AOX1  EPHA5  HES1   Supplementary Table 1 . known therapeutic targets of CML. CYP1A1   CREBBP  D6S231E  PHD  DNMT1  FGR  KIR2DL2   NOTCH1  CBP  CTEPH1  CA2  SLC01A2  FRK  PRAME   KDR  RSTS1  HLA-B  NR1I2  HSD11B1  HSPA8  SMO   NFE2L2  MYH11  SPDA1  POMC  ALB  ZAK  ORM1   HLA-G  AAT4  HLA-DPB1  CALM1  RARA  PPAT  MSR1   CASP3  FAA4  TREM2  YARS  RARB  CYP3A4  NUMB   ABCG2  FUS  MYB  TAT  1KBKB  CYP1A2  CAMK2G   EZH2  TLS  ALL2  SLC16A2  TXNRD1  CYP1B1  CCDC170   CDKN1B  ALS6  MLSM7  TFPI  MAPK3  FM03  GPX3   JUN  ETM4  DEL7q  GNRHR  MAPK1  RET  MIR451A   ERCC2  CBFB  C7DELq  KCNQ2  CDKN1A  NTPK1  CDK7   TNFSF10  PEBP2B  NCF1  KCNQ3  HDAC1  CSF1R  MIR101-1   RHOA  DIA4  PRSS2  HTR3A  PML  DDR1  IRF8   WT1  NMOR1  TRY2  GRIA1  ADA  CYP3A7  KIR2DS4   PDCD1  CYBA  SCLL  GNB1  CD38  CYP2C9  ID4   LGALS3  NF1  NSD3  MRD42  CD19  CYP2D6  CD33   CYP3A5  VRNF  WHSC1L1  CTRC  RXRA  CYP2C19  KIR2DS1   CD274  WSS  SLC20A2  CLCR  RXRG  PTGS1  HMMR   KCNH2  NFNS  MLVAR  IMD22  1GFBP3  SLC22A2  SOCS2   LCN2  ERBB2  GLVR2  TPOR  PSG5  ABCA3  BLK   AURKA  NGL  IBGC1  MPLV  CSF2RA  CYP2C8  RMND1   RUNX1  NEU  NBN  THCYT2  1L3RA  UGT1A1  MIR224   LEPR  HER2  NBS1  TAL1  SDC2  GSTA2  RANGAP1   HSP90AA1  MSF  THCYT3  TCL5  PRG2  MGST2  FUT1   NPM1  MSF1  LALL  SCL  EPOR  FLT3  PCM1   AKAP12  NAPB  BSAP  BCL10  GPRC5A  RPI2  MIR130A   BCL2L1  SH3GL1  ALL3  IMD37  NROB1  RPL3  MIR7-1   MCL1  EEN  TAL2  GFI1  ALDH1A2  TEK  AHI1   IL2RA  LYL1  CLLS3  ZNF163  RARRES1  FGFR1  CDKN2C   PLK1  CEBPA  CHDSKM  SCN2  LCN1  FGFR2  ZBTB2   PTPN22  CEBP  NUP214  RBM15  OBP2A  FGFR3  PLCD1   XIAP  BCL3  D9S46E  SPEN  RBP4  FGFR4  MTSS1   BCL2L11  BAX  CAN  OTT  PDK4  LCK  MSI2   DPP4  TAM  CAIN  IGFR2  CYP26A1  SRC  FERMT3   SYK  MST  AF10  CD32  HPGDS  ABCB11  PIWIL1   PDGFRA  CBFA2  ALL1  PBX1  ATP1A1  FCGR3B  RAPGEF1   MIR155  AML1  MBL2  CAKUHED  DGUOK  C1R  MKNK1   TWIST1  CML  MBL  ABL2  1TGAL  C1QA  EHMT1   CBL  PHL  MBP1  ABLL  TOP2A  C1QB  USF2   STAT5A  ALL  MBL2D  ARG  PDLA1  C1QC  MIR10A   BMI1  HMOX1  MBPD  NCF2  CBR1  FCGR3A  IL1RAP   HSPA4  HMOX1D  LMO1  FLVCR1  AKR1A1  C1S  MIR320A   TGM2  NCF4  RBTN1  AXPC1  AKR1  FCGR1A  LTB4R2   NFKBIA  P40PHOX  RHOM1  PCARP  NQO1  FCGR2A  SETBP1   5682 CD34   CGD3  LMO2  COPD  NOS3  FCGR2B  ULBP2   CALR  MKL1  RBTNL1  TCL4  NDUFS3  FCGR2C  BTG1   MIR34A  AMKL  RHOM2  ERBB4  NDUFS7  RRM2  KDM5A   XRCC3  MAL  TTG2  HER4  POR  DCK  MLLT3   PDGFRB  XK  CLLS1  ALS19  ABCC3  PRKAR2A  PHF6   SOCS1  MCLDS  SMAR  SGOL1  HPRT1  PRKAR1A  CD7   ABCC1  CYBB  NUMA1  SGO  TUBB  PDE3A  PTPRG   IFNA1  CGD  PICALM  SGO1  TUBA4A  1FNAR1  FCER1G   PIK3CG  AMCBX2  CALM  CAID  DHFR  FNTB  HULC   CYP2B6  IMD34  CLTH  THRB  FPGS  PDGFD  MIR196B   EIF4E  GATA1  LAP  ERBA2  TYMS  FLT1  MR1   XPC  GF1  ATA  THR1  ATIC  FLT4  RIN1   AURKB  ERYF1  AT1  PRTH  GGH  UGT1A3  ST3GAL4   PTPN6  NFE1  ZBTB16  MYD88  FOLR1  UGT1A4  FIP1L1   DNMT3A  XLTDA  ZNF145  MYD88D  IFNAR2  UGT1A9  MIR148B   BCL6  XLTT  PLZF  DCML  NS3  UGT2B7  MIR326   ALOX5  XLANP  KMT2A  MONOMAC  4A  UGT2B15  MIR486-1 
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